Pay in 4 interest-free payments of $7.15 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
The programme spans multiple trials targeting distinct endpoints: On 21 May 2026 Eli Lilly reported topline results from TRIUMPH-1, the pivotal Phase 3 obesity trial and the programme's first Phase 3 efficacy readout: in 2,339 adults, mean weight loss at the 80-week primary endpoint reached 19.0% (4mg), 25.9% (9mg), and 28.3% (12mg) versus 2.2% for placebo (Eli Lilly investor release
Weight gain after stopping Ozempic or other GLP-1 medications is not a sign of personal failure
[16] What began as a side effect quickly became the main event
Suggested Dosage and Directions: Shake well before opening
The degree of structural damage present initially may influence durability of response
US$ 24.87
US$ 24.44
US$ 27.86
US$ 25.56
US$ 26.25
US$ 22.44
US$ 25.10
US$ 20.29
